Clinical Trial Update: A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Rocbrutinib versus investigator's choice of BTK inhibitors in relapsed or refractory Mantle Cell Lymphoma; the study is currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Rocbrutinib (rocbrutinib)

Snippet

Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. | Conditions: Mantle Cell Lymphoma | Phase 3 | Status: RECRUITING